BOSTON, MA — UltraSight™, a leader in AI-guided cardiac workflows with its Echosystem platform, today announced it has raised $24 million in Series B2 financing. The financing will support UltraSight’s commercial expansion in the United States and fund the development of new high-value workflows for the intensive care unit and circulatory support settings, where time-critical imaging decisions directly shape patient management. The proceeds will also support strategic collaborations to expand adoption of the Echosystem product line as it integrates proprietary AI innovations across time-critical cardiac care pathways.
The financing was led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures. Existing investors Mayo Clinic Ventures, NYU and Iron Nation also participated.